DB-3Q for the Treatment of Medically Refractory Crohn's Disease | MicrobiomeTrials← Back to trialsNCT07625293
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-01Est. Completion: 2027-06
Enrollment target: 36 participants Locations- Washington University, St. Louis, St Louis, Missouri, United States
Other microbiome trials you might be interested in
Moderate to Severe Crohn's Disease
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy…
Phoenix, United StatesEst. completion Apr 30, 2026
Crohn DiseaseColitis, Ulcerative
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medic…
Bristol, United StatesEst. completion Dec 17, 2037
Phase 4
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with ada…
Dothan, United StatesEst. completion Jun 28, 2027